Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options

Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
CME, CPE
Ajay K. Nooka, MD, MPH, FACP
Release Date: October 14, 2019
Expiration Date: October 14, 2020

Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Nooka covers the key aspects of management including the predictive measures currently available for risk stratification in newly diagnosed multiple myeloma (NDMM). He will also discuss the key clinical- and patient-related factors that could influence your choice of induction regimen, the safety and efficacy of the current modern day induction regimens in the frontline setting, as well as the role of monoclonal antibodies and the treatment of newly diagnosed myeloma patients in frontline setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
Begin, Earn CreditView Only, No CreditGet Certificate